The tweet was deleted by the author.
But we saved everything 🙂.
Climb Bio, Inc. is advancing B cell-directed therapies in the treatment of IgA nephropathy (IgAN), signaling growing momentum for approaches targeting the APRIL protein.
At the National Kidney Foundation B Cell Workshop in Dallas, industry experts and researchers showed strong enthusiasm about the clinical potential of APRIL-targeted interventions, while raising key questions surrounding implementation and next steps as these therapies progress through development. IgAN remains a significant unmet need, and the dialogue reflects increased commitment within the clinical research community to accelerate novel solutions.
Climb Bio, Inc. recently participated in an initiative to advance patient-centered, scientifically rigorous IgA nephropathy clinical trials. The company also scheduled a webcast with Dr. David Jayne to explore budoprutug and anti-CD19 therapy opportunities. These efforts add to Climb Bio’s focus on innovative B cell-directed approaches in kidney disease.